The Prostate · 2026
Stage-Specific Racial Disparities in Prostate Cancer Survival Outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Minas Tsion Zewdu, Butler Eboneé Nicole, Mwamburi Samuel Mwakisha, Dorsey Tiffany H, Bedi Deepa, Dean-Colomb Windy, Loffredo Christopher A, Ambs Stefan, Yates Clayton
Аннотация
BACKGROUND: Racial disparities in prostate cancer (PCa) survival are inconsistently reported.
METHODS: We evaluated long-term survival in 976 men from the NCI-Maryland PCa case-control study, stratified by disease stage.
RESULTS: There were no survival differences observed between African American (AA) and European American (EA) men with Stage 1 or 2 disease. In contrast, AA men with Stage 3 or 4 PCa experienced significantly higher prostate cancer-specific and all-cause mortality in equal-access Veterans Affairs (VA) and non-VA settings. Adjustment for baseline prostate-specific antigen (PSA) level, Gleason score, and treatment modalities attenuated but did not eliminate these differences.
CONCLUSIONS: Disparate survival outcomes for AA men with PCa emerge mainly at Stage 3 or 4 diagnosis, emphasizing the importance of early detection for these men. Notably, AA patients with advanced-stage disease were more likely to receive hormone therapy alone, a treatment pattern that may contribute to racial disparities in PCa survival.
METHODS: We evaluated long-term survival in 976 men from the NCI-Maryland PCa case-control study, stratified by disease stage.
RESULTS: There were no survival differences observed between African American (AA) and European American (EA) men with Stage 1 or 2 disease. In contrast, AA men with Stage 3 or 4 PCa experienced significantly higher prostate cancer-specific and all-cause mortality in equal-access Veterans Affairs (VA) and non-VA settings. Adjustment for baseline prostate-specific antigen (PSA) level, Gleason score, and treatment modalities attenuated but did not eliminate these differences.
CONCLUSIONS: Disparate survival outcomes for AA men with PCa emerge mainly at Stage 3 or 4 diagnosis, emphasizing the importance of early detection for these men. Notably, AA patients with advanced-stage disease were more likely to receive hormone therapy alone, a treatment pattern that may contribute to racial disparities in PCa survival.